Engineering “off-the-shelf” TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality
Shan He, Yirong Dai, Qi Chen, Adeline Chia, Joey Lim, Shou Kit Hang, Joey Aw, Andrea Pavesi, Rajneesh Kumar, Thinesh Lee Krishnamoorthy, Antonio Bertoletti, Anthony Tanoto Tan · 2026
Read Engineering “off-the-shelf” TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality by Shan He, Yirong Dai, Qi Chen, Adeline Chia, Joey Lim, Shou Kit Hang, Joey Aw, Andrea Pavesi, Rajneesh Kumar, Thinesh Lee Krishnamoorthy, Antonio Bertoletti, Anthony Tanoto Tan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13631606.txt.
Description
Shan He and co-authors build an off-the-shelf version of TCR-T cell therapy, where T cells are engineered to hunt a target. Published in 2026, the work uses cells aimed at hepatitis B antigens on liver cancer cells, delivered by mRNA so the effect fades and toxicity stays limited. Cells from cancer patients proved poor starting material, so healthy donor cells are used.
Donor cells raise two risks: the host may reject them, and they may attack the host. The team counters the first with a short course of immune suppression plus drug resistant armored cells. A tuned cytokine mix counters the second, cutting alloreactivity while keeping strong killing of target cells. The study is an in vitro proof of concept.
Catalog record
| CREATOR | Shan He, Yirong Dai, Qi Chen, Adeline Chia, Joey Lim, Shou Kit Hang, Joey Aw, Andrea Pavesi, Rajneesh Kumar, Thinesh Lee Krishnamoorthy, Antonio Bertoletti, Anthony Tanoto Tan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |